Skip to main content
Top

Drugs

Issue 5/2021

Content (12 Articles)

MicroRNA Mimics or Inhibitors as Antiviral Therapeutic Approaches Against COVID-19

Christine Hum, Julia Loiselle, Nadine Ahmed, Tyler A. Shaw, Caroline Toudic, John Paul Pezacki

Ansuvimab: First Approval

Arnold Lee

Margetuximab: First Approval

Anthony Markham

Voclosporin: First Approval

Young-A Heo

Comment on “Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update”

Udo Bonnet, Heath McAnally, Norbert Scherbaum

Authors’ Reply to Bonnet et al. “Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update”

Kirk E. Evoy, Sarvnaz Sadrameli, Jillian Contreras, Jordan R. Covvey, Alyssa M. Peckham

Correction to: Lonafarnib: First Approval

  • Open Access
  • Correction

Sohita Dhillon

Keynote webinar | Spotlight on dry eye disease

  • Live
  • Webinar | 28-05-2026 | 13:00 (CEST)

DED is highly prevalent yet challenging to diagnose and treat. Join leading experts to explore the latest developments and gain practical guidance on effective management in busy clinical settings. Brought to you by Springer Medicine and Eye.

Watch it live: 28 May 2026, 13:00–14:00 (CEST)

Prof. Harminder Dua
Prof. Sajjad Ahmad
Prof. Anat Galor
Join the webinar
Webinar
Image Credits
Conceptual illustration of dry eye disease/© Science Photo Library / Getty Images